Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole tran… Read more
Personalis Inc (PSNL) - Net Assets
Latest net assets as of September 2025: $171.41 Million USD
Based on the latest financial reports, Personalis Inc (PSNL) has net assets worth $171.41 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($242.84 Million) and total liabilities ($71.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $171.41 Million |
| % of Total Assets | 70.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | 4.11% |
| 10-Year Change | N/A |
| Growth Volatility | 50.62 |
Personalis Inc - Net Assets Trend (2017–2024)
This chart illustrates how Personalis Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Personalis Inc (2017–2024)
The table below shows the annual net assets of Personalis Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $202.96 Million | +56.79% |
| 2023-12-31 | $129.44 Million | -40.66% |
| 2022-12-31 | $218.14 Million | -29.70% |
| 2021-12-31 | $310.30 Million | +59.17% |
| 2020-12-31 | $194.94 Million | +82.72% |
| 2019-12-31 | $106.69 Million | +200.28% |
| 2018-12-31 | $-106.39 Million | -14.89% |
| 2017-12-31 | $-92.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Personalis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45437100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.00% |
| Other Comprehensive Income | $-23.00K | -0.01% |
| Other Components | $752.96 Million | 371.00% |
| Total Equity | $202.96 Million | 100.00% |
Personalis Inc Competitors by Market Cap
The table below lists competitors of Personalis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JAPAN AVIATION EL.
F:8N9
|
$374.64 Million |
|
Synmosa Biopharma
TWO:4114
|
$374.66 Million |
|
Aditya Birla Fashion and Retail Limited
NSE:ABFRL
|
$374.74 Million |
|
Suzhou HYC Technology Co Ltd
SHG:688001
|
$374.79 Million |
|
Digital Turbine Inc
NASDAQ:APPS
|
$374.51 Million |
|
Vox Royalty Corp. Common Stock
NASDAQ:VOXR
|
$374.45 Million |
|
Hbt Financial Inc
NASDAQ:HBT
|
$374.41 Million |
|
Suzhou Etron Technologies Co Ltd
SHG:603380
|
$374.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Personalis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 129,441,000 to 202,957,000, a change of 73,516,000 (56.8%).
- Net loss of 81,284,000 reduced equity.
- New share issuances of 97,824,000 increased equity.
- Other comprehensive income increased equity by 199,000.
- Other factors increased equity by 56,777,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-81.28 Million | -40.05% |
| Share Issuances | $97.82 Million | +48.2% |
| Other Comprehensive Income | $199.00K | +0.1% |
| Other Changes | $56.78 Million | +27.97% |
| Total Change | $- | 56.79% |
Book Value vs Market Value Analysis
This analysis compares Personalis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-4.26 | $7.12 | x |
| 2018-12-31 | $-4.89 | $7.12 | x |
| 2019-12-31 | $5.92 | $7.12 | x |
| 2020-12-31 | $5.67 | $7.12 | x |
| 2021-12-31 | $7.07 | $7.12 | x |
| 2022-12-31 | $4.77 | $7.12 | x |
| 2023-12-31 | $2.69 | $7.12 | x |
| 2024-12-31 | $3.43 | $7.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Personalis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -96.06%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.33x
- Recent ROE (-40.05%) is below the historical average (-30.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -251.23% | 0.28x | 0.00x | $-14.34 Million |
| 2018 | 0.00% | -52.64% | 0.91x | 0.00x | $-9.25 Million |
| 2019 | -23.51% | -38.47% | 0.41x | 1.47x | $-35.75 Million |
| 2020 | -21.18% | -52.49% | 0.32x | 1.26x | $-60.77 Million |
| 2021 | -21.02% | -76.29% | 0.22x | 1.28x | $-96.26 Million |
| 2022 | -51.95% | -174.20% | 0.22x | 1.34x | $-135.13 Million |
| 2023 | -83.66% | -147.38% | 0.33x | 1.74x | $-121.24 Million |
| 2024 | -40.05% | -96.06% | 0.31x | 1.33x | $-101.58 Million |
Industry Comparison
This section compares Personalis Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Personalis Inc (PSNL) | $171.41 Million | 0.00% | 0.42x | $374.63 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |